Coya Therapeutics’ (COYA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Thursday,Benzinga reports. D. Boral Capital currently has a $18.00 price target on the stock.

Separately, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, March 20th.

Coya Therapeutics Stock Down 4.8 %

NASDAQ COYA opened at $6.56 on Thursday. The stock has a market cap of $109.72 million, a P/E ratio of -10.09 and a beta of 0.31. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.24. The company’s 50-day simple moving average is $6.43 and its 200 day simple moving average is $6.52.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.10 million. Research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Trading of Coya Therapeutics

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its position in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $59,000. Jane Street Group LLC bought a new stake in shares of Coya Therapeutics during the fourth quarter valued at approximately $74,000. Northern Trust Corp increased its holdings in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in Coya Therapeutics in the 4th quarter worth approximately $401,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.